Chrysoeriol inhibits U46619-induced human platelets aggregation through regulation of phosphoprotein and granule secretion

Cardiovascular disease has emerged as a major health problem worldwide, and excessive platelet activation and aggregation have been identified as the main causes of cardiovascular disease.Therefore, controlling platelet activation is a key strategy in the prevention and treatment of cardiovascular disease.Chrysoeriol is a major flavonoid compound present in the traditional herbal preparation Dangguisusan, and previous studies have reported that it has anti-inflammatory, antioxidant, and anticancer effects.However, the efficacy and mechanism of chrysoeriol in inhibiting platelet activation and aggregation have not been clearly identified.This study confirmed the effect of chrysoeriol on U46619-induced human platelets and clarified its mechanism of action.Chrysoeriol inhibited the phosphorylation of phosphoproteins Phosphatidylinositol 3-kinase/protein kinase B and MAPK during platelet activation, and also inhibited the phosphorylation of cytosolic phospholipase A2.In addition, chrysoeriol reduced intraplatelet granule release, including ATP and serotonin release.As a result, chrysoeriol potently inhibited U46619-induced platelet aggregation.Through these results, this study shows that chrysoeriol can be an effective antithrombotic agent that inhibits human platelet activation and aggregation by blocking granule release through regulation of phosphoproteins.